Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: 10.71%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Neutral
Protalix demonstrated strong revenue growth and successfully completed a Phase 1 trial for PRX-115, but faced challenges with decreased R&D service revenues and lower net income.Company Guidance
In the Protalix BioTherapeutics fiscal year 2024 conference call, the company reported record revenues of $53 million, a 31% increase from the previous year. This growth was driven primarily by an $11.8 million increase in sales to Chiesi and additional sales to Brazil and Pfizer. The company also noted a reduction in research and development expenses by 24% to $13 million, due to the completion of the Fabry clinical program. Their cash position at the end of 2024 was $34.8 million, while they achieved a net income of $2.9 million. Protalix highlighted significant progress in their pipeline, including the completion of a Phase 1 clinical trial for PRX-115 and preparations for a Phase 2 study. They also emphasized their partnership with Chiesi and the anticipated growth in royalty revenues from Elfabrio, projecting revenues north of $100 million by 2030.Record Revenue Growth
Protalix recorded revenues of $53 million for fiscal year 2024, marking a 31% increase compared to $40.4 million in 2023, driven primarily by increased sales to Chiesi.
Debt Repayment
Protalix repaid in full all outstanding principal and interest under its 7.5% senior secured convertible promissory notes, strengthening its balance sheet.
Successful Phase 1 Trial for PRX-115
The company completed all cohorts in the Phase 1 clinical trial of PRX-115, with positive results that support moving into a Phase 2 trial.
Reduced Expenses
Research and development expenses decreased by 24% to $13 million, and selling, general and administrative expenses decreased by 19% to $12.2 million.
---
PLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $2.24 | $2.45 | +9.37% |
| Nov 14, 2024 | $1.24 | $1.41 | +13.71% |
| Aug 14, 2024 | $1.04 | $0.93 | -10.58% |
| May 10, 2024 | $1.25 | $1.10 | -12.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Protalix Biotherapeutics (PLX) report earnings?
Protalix Biotherapeutics (PLX) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Protalix Biotherapeutics (PLX) earnings time?
Protalix Biotherapeutics (PLX) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLX EPS forecast?
PLX EPS forecast for the fiscal quarter 2025 (Q1) is 0.03.
---